Patents by Inventor Natacha Prevost

Natacha Prevost has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
    Patent number: 10125125
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: November 13, 2018
    Assignee: Active Biotech AB
    Inventors: Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
  • N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS
    Publication number: 20180155330
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between SI 00A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: December 8, 2017
    Publication date: June 7, 2018
    Inventors: Ingela FRITZSON, David LIBERG, Stephen EAST, Colin MACKINNON, Natacha PREVOST
  • N-(heteroaryl)-sulfonamide derivatives useful as S100-inhibitors
    Patent number: 9873687
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: January 23, 2018
    Assignee: Active Biotech AB
    Inventors: Ingela Fritzson, David Liberg, Stephen East, Colin Mackinnon, Natacha Prevost
  • Compounds useful as S100-inhibitors
    Patent number: 9771372
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: September 26, 2017
    Assignee: Active Biotech AB
    Inventors: Ulf Wellmar, David Liberg, Maria Ekblad, Marie Bainbridge, Stephen East, Jonathan Hargrave, Natacha Prevost
  • NOVEL COMPOUNDS USEFUL AS S100-INHIBITORS
    Publication number: 20170204098
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: May 22, 2015
    Publication date: July 20, 2017
    Inventors: Ulf WELLMAR, David LIBERG, Maria EKBLAD, Marie BAINBRIDGE, Stephen EAST, Jonathan HARGRAVE, Natacha PREVOST
  • 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
    Patent number: 9346816
    Abstract: The present invention relates to compounds defined by formula I wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: May 24, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Stephan-Georg Mueller, Christopher John Brown, Alexander Heifetz, Bernd Nosse, Juergen Prestle, Natacha Prevost, Klaus Rudolf, Stefan Scheuerer, Marcus Schindler, Dirk Stenkamp, Leo Thomas, Heather Tye
  • N-(HETEROARYL)-SULFONAMIDE DERIVATIVES USEFUL AS S100-INHIBITORS
    Publication number: 20160115158
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound. The compound is an inhibitor of interactions between S100A9 and interaction partners such as RAGE, TLR4 and EMMPRIN and as such is useful in the treatment of disorders such as cancer, autoimmune disorders, inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: May 14, 2014
    Publication date: April 28, 2016
    Inventors: Ingela FRITZSON, David LIBERG, Stephen EAST, Colin MACKINNON, Natacha PREVOST
  • 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
    Publication number: 20140066428
    Abstract: The present invention relates to compounds defined by formula I wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
    Type: Application
    Filed: November 5, 2013
    Publication date: March 6, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan-Georg MUELLER, Christopher John BROWN, Alexander HEIFETZ, Bernd NOSSE, Juergen PRESTLE, Natacha PREVOST, Klaus RUDOLF, Stefan SCHEUERER, Marcus SCHINDLER, Dirk STENKAMP, Leo THOMAS, Heather TYE
  • 6,7,8,9-Tetrahydro-5H-1,4,7,10a-tetraaza-cyclohept[f]indene derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
    Publication number: 20120165304
    Abstract: The present invention relates to compounds defined by formula (I), wherein the groups X, Y, W and R1 to R4 are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are agonists of the 5-HT2C receptor, and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this receptor, such as metabolic and CNS-related disorders.
    Type: Application
    Filed: November 26, 2009
    Publication date: June 28, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Stephan-Georg Mueller, Christopher John Brown, Alexander Heifetz, Bernd Nosse, Juergen Prestle, Natacha Prevost, Klaus Rudolf, Stefan Scheuerer, Marcus Schindler, Dirk Stenkamp, Leo Thomas, Heather Tye